News Related to Nephrotic Syndrome

Related coverage linked through entity extraction aliases.

FDA grants full approval to Filspari for focal segmental glomerulosclerosis

Apr 14, 2026

The FDA granted full approval to Filspari to reduce proteinuria in patients aged eight and older with FSGS without nephrotic syndrome. The decision was based on Phase III DUPLEX data versus irbesartan.

Pediatric hypertriglyceridemia guidance sharpens risk-based screening and management

Apr 08, 2026

Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.